Logo1
ASTS - American Transplant Congress 2015 - Nurses and Pharmacists Only
Mr pencil

How would you like your name to appear on your certificate?



What activities did you attend at the event?
Agreement
By completing this form, you attest that you have participated in all selected activities in thier entirety.
PHARMACISTS AND PHARMACY TECHNICIANS ONLY -- Please provide the following:
NABP eProfile ID (ePID):
Date of Birth (MM/DD) - Example September 24 would be 0924:
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Please rate the speaker(s) as a group.  You will have the opportunity to elaborate on an individual speaker in the following question. 
Objective 1: Discuss the latest technological advances in transplant research, clinical and surgical practices.
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
If you have additional comments regarding the session or individual speaker(s) - e.g. teaching ability, expertise, organization of materials, etc. - please use the space below:
Objective 2: Identify the challenges of patient management, social, ethical, and political issues in the transplantation community.
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
Objective 3: Apply current treatment and disease prevention strategies for transplant recipients.
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
Describe the rationale and goals of immune monitoring in lung transplantation
Discuss the approach in immune monitoring
Describe the incidence of acute cellular rejection after heart transplantation and the current modalities for rejection surveillance
Discuss potential methods for early identification of chronic lung allograft rejection, including immune surveillance for antibody-mediated rejection and potential assays for early detection of bronchiolitis obliterans
Discuss common cellular and molecular mechansims of tolerance.
Describe the epidemiology of recurrent glomerulopathies.
Discuss adjustment of immunosuppression as a management tool for BK virus infection.
Explain how GFR estimating equations are derived and their limitations
Discuss the clinical and laboratory features of chronic AMR
Describe prevention strategies for metabolic syndrome.
Explain the roles of CMS in the oversight of transplantation.
Identify 3 venues available to learn about current transplant related policies, pending policy revisions, and archived policies.
Provide the basis and motivation for a rigorous data management process.
Dsicuss CUSUM and its role in transplant outcomes prediction
Explore ways that SRTR program specific reports can be used to improve quality and outcomes
Recognize factors that limit resectability of intraheaptic cholangiocarcinoma.
Discuss actual diagnostic procédures and treatment of hepatobiliary (HB) neuro-enndocrine tumors (NET)
Discuss the limitations of surgery for treatment of cholangioCa in 2015
Name the indications and selection criteria for neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma
Discuss selection of patients beyond the Milan criteria for liver transplant the principles of selecting resection vs transplantation for HCC
Recognize manifestations of interesting parasitic infections in SOT recipients
Discuss cutting edge diagnostic and therapeutics techniques in the field of transplant infectious disease
Explain how immunosuppression affects vaccination
Describe the epidemiology and outcomes associated with LVAD infections
Outline management options for latent TB in transplantation
Discuss advances in immunology and their relevance to the transplantation field
Discuss development of B cells into mature lineages and B cell tolerance
Identify the 10 most important basic immunology findings in 2014 and their implications to basic transplantation research
Define the role of complement in alloimmunity
Discuss how naive T-cells are activated and polarized into effector Th cells
Identify conditions that result in the generation of alloreactive memory T cells
Discuss the complement-dependent effector mechanisms of antibodies
Discuss modalities to diagnose and treat rejection
Discuss the difficulty in regulating the intensity of the alloimmune response.
Explore the definitions of tolerance utilized as an endpoint for clinical trials
Review interpretation of C4d stains in liver
Demonstrate the pathophysiology of antibody mediated injury
Define the risk of AMR In liver transplant recipients
Describe how to diagnose rotavirus and norovirus in SOT recipients
List strategies to prevent and potentially treat rotovirus and norovirus infections in SOT recipients
Explain the interactions of the microbiome with the human host
Review the data for fecal microbiota transplantation for the treatment of clostridium difficile infections
Discuss the concept of liver transplantation tolerance
Discuss cellular and molecular mechanisms underlying the regulation of the immune system by liver allografts
Discuss the identity of antigen-presenting cells (APCs) in the liver
Discuss optimal selection of redo lung transplant candidates
Identify strategies to improve allograft function and survival the second time around
Review the registry data available for re-do lung transplantation
Discuss the risks and benefits of such critical practice
Discuss recommendations from the Consensus Conference on Transplant Program Quality and Surveillance
Review current quality metrics used in organ transplantation
Describe the role the OPTN/UNOS Data Advisory Committee plays in determining data collected on transplant donors and recipients
Describe ways in which potential new data elements might be incorporated into OPTN/UNOS collection and statistical analysis
Discuss why standardized order sets are part of the ongoing health care improvement act
Outline effective strategies for standardized order set design procedures
Summarize major mechanistic pathways for drug-drug interactions of immunosuppressant's
Explain belatacept REMS program components
Review generalizable information for CPOE enhancements to customize clinical decision support for REMS programs fulfillment.
Identify the prevalence of psychological disorders in the solid-organ transplant population
Describe the prevalence of risk taking behavior, including treatment non-adherence, in adolescents with chronic medical conditions, including transplantation where available
Identify the normal pubertal milestones
Identify special issues pertaining to transplant patients
Elucidate the mechanisms involved in DSA+ patients leading to AMR or protecting from antibody-mediated damage using microarrays.
Explain how different platforms may yield different results.
Review current strategies for cellular immune risk-stratification of transplant candidates
Described ongoing research and future clinical applications
Discuss the history of attempts to achieve tolerance in solid organ transplantation
Discuss if CD40 blockade affects the number of B-cells or not
Define the role of Pi3K pathway in Tregs survival
Describe the benefits of inflammatory blockade to improve islet graft outcome
Review prognosis and need for BK prevention strategies
Define role of quinolones to prevent BK virus infection
Discuss the risk of Transfusion-Transmitted Viral Infections
Describe the novel trial design incorporated to evaluate current bioequivalence testing methods for tacrolimus and its application to transplant recipients.
Review the results of the study Understand the applicability of these results to current clinical practice.
Provide an overview of the metabolic and transporter pathways involved in tacrolimus absorption, distribution, metabolism and elimination (ADME)
Describe how differences in genotype could affect bioequivalence testing.
Identify the benefits of transplantation in the elderly
Discuss how the benefits and risks of transplantation in the elderly vary by donor source
Discuss the frailty phenotype and its role in transplantation
Discuss the current liver allocation system (Share 35) and the rationale for modifying it.
Identify advantages and risks of potential strategies for decreasing geographic variation in access to liver transplantation.
Discuss the predictors of, the impacts of, and the possible solutions to geographic disparities in liver allocation
Discuss the risk of end-stage kidney disease after living kidney donation.
Discuss selecting controls for donors of living donation
Propose new ways of thinking about donor risks.
Discuss health consequences of decreased kidney function
Explain the role of chimerism in development of transplantation tolerance
Discuss the discovery and role of the facilitating cell in stem cell transplantation
Discuss the current status of tolerance induction in HLA-matched kidney transplantation
Discuss how to approach operative issues and how to save the kidney.
Differentiate between standard and complex technical issues in renal transplantation
Explore intraoperative assessment and decision making, and its impact on the management of technical issues
Discuss indications for heart/kidney transplant and with HK transplant outcomes
Explain the technique of combined heart liver transplantation
Identify limitations of combined heart-lungtransplantation and its availability.
Explain the role for long noncoding RNA in Inflammation
Discuss which microRNAs have been shown to regulate immune responses after transplant
Discuss the structure and regulation of long noncoding RNAs
Describe current and new mechanisms of action of Tregs.
Discuss new approaches to develop therapeutic Tregs for use in transplantation.
Explain how perturbation of regulatory T cell metabolism affects their function
Discuss the developmental plasticity of the organ
Discuss the news in the field of insulin producing cell differentiation from stem cells
Explain the need for cell therapy in diabetes
Describe the process for implementing collaborative practice agreements
Identify key elements needed in successful collaborative practice agreements
Explain the process to measure outcomes and impact of implementation of collaborative practice agreements.
Discuss the complex process involved in human islet isolation for improving islet yield.
Describe various techniques utilized for digesting chronic pancreatitis pancreas to maximize islet yield
Describe the three major outcomes of TPIAT.
Discuss surgical technique to optimize islet recovery.
Identify options that exist for neonatal transplant and research donations and the constraints surrounding both types of donation
Utilize new resources to make neonatal donation easier for their organization
Explain the benefits of medical research gained by the donor family and the medical community.
Outline basic steps that can be taken to ensure an optimal outcome for potential donor families of neonates.
Discuss how the autoimmune response is normally controlled
Discuss whether aberrant responses to certain self antigens damage the transplant
Discuss immune responses to lung associated self-antigens and their role in rejection
Interprete laboratory findings related to AMR
Discuss correlations between DSA and biopsy findings
Discuss therapeutic options in cases of atypical AMR.
Discuss therapeutic options in cases with AMR complicated with other pathological entities.
Discuss basic principles of a new field of biology, the long non-coding RNAs
Discuss the pathways that lead to immune dysregulation after injury
Discuss that viral and bacterial infections can generate memory T cells that can cross-react with donor antigens following transplantation
Appreciate the possibility of therapeutic intervention in necroptosis and other forms of regulated necrosis
Describe contribution of innate immune cells to lung rejection
Recognize the extent of benefit conferred by early, diligent cysteamine therapy with respect to maintenance of renal function and growth in cystinosis.
Name the benefits of cysteamine therapy regarding non-renal complications of cystinosis.
Discuss the extension of basic science observations to clinical transplant medicine
Identify the key clinical challenges facing waitlisted liver transplant candidates
Recognize the value of multidisciplinary interactions in the world of multiorgan transplantation
Delineate strategies for successful manuscript acceptance
Recognize the importance of optimal medication management for transplant recipients
Manage immunosuppression with associated chronic infectious diarrhea.
Identify the risk factors for developing New Onset Diabetes After Transplant
Distinguish between using obesity as a way of discriminating against transplant candidates and prospective donors vs. as a screening criterion used for harm reduction prior to surgery or for improved outcomes post surgery.
Identify the optimal time after transplantation to address sun protection
Conceptualize the immunologic risk assignment for sensitized kidney transplant recipients.
Discuss pathophysiology of oxalosis
Discuss outcomes with transplantation in these patients
Review the clinical manifestations of MMA and PA
Explain appropriate risk-benefit discussions that pertain to transplantation for inborn metabolic disorders.
Describe the definition of organizational health literacy and its potential application in the care of transplant patients
Discuss methods to evaluate organizational health literacy in clinical practice and also research
List common reasons for nonadherence in adolescent transplant patients
Describe cognitive factors in adolescence that impact adherence
Identify strategies that can help restore adherence in a setting in which cognitive barriers are present
Discuss the risk factors for ETOH recidivism
Review the 6 month rule
Compare transplant outcomes of alcoholic liver transplant recipients by recidivism rates
Articulate ethical concerns about informed consent for live liver donors
Discuss the effects of the new allocation system on wait list management
Discuss the new CPRA categories and sliding scale points
Identify the large problem of mortality on the wait list
Consider the risks and benefits of medical tests for wait-listed patients
Utilize synthetic biology to design receptors that can be expressed in T cells to recognize cancer cells
Implement phase 1 clinical trials testing novel T cell therapeutics
Discuss inter-species grafting of tissues and organs
Discuss principles of liver development relevant to directed hepatocyte differentiation
Discuss current transplant payment models
Descibe the history of Value in Transplantation
Discuss where the Future State of Value in Transplantation will come from.
Define value in transplantation
Discuss history of legislation related to HIV and organ transplantation
Discuss key knowledge gaps related to HIV to HIV transplantation
Discuss ethical considerations when using HIV positive donors
Discuss research criteria for HIV+ to HIV+ organ transplantation under the HIV Organ Policy Equity (HOPE) Act
Describe failures with conventional therapy for AMR after lung transplantation
Identify limitations associated with AMR therapy after lung transplantation
Discuss why HLA antibodies occur
Outline the limitations of HLA antibody testing methods
Discuss quantification and characterization of HLA antibodies and how it relates (or not) to antibody impact.
Identify new indications for intestinal transplant
Define the role of Donor Specific Antibody Monitoring in Intestinal Transplantation
Outline the current indications for enteroplasties in children and adults with short bowel syndrome
Discuss short and long term complications of enteroplasties, and overall success rates
Discuss the national landscape of induction immunosuppression use for HIV (+) kidney transplant recipients.
Describe that liver allograft tolerance is associated with a signature of 9 differential miRNAs before immunosuppression withdrawal
Identify risk factors for the presence of interface activity in pediatric liver allografts with normal liver tests
Describe the potential benefits and potential limits of cell free DNA as a biomarker for rejection in heart transplantation
Discuss the nature of public molecular data
Describe how publicly-available molecular measurements can be used to find new uses for drugs.
Define the genome, and how it could help with diagnostics and prognostics
Describe the impact of HCV on non-liver transplant recipients
Review current therapies for HCV in non-liver waitlisted and transplanted patients
List the benefits of HCV eradication following liver transplantation and define agents used
Discuss the renal and hepatic factors that influence use of different antiviral drug combinations
Ascertain the best patient characteristics for consideration of pre-transplant antiviral therapy
Review the molecular regulation of apoptotic cell death
Discuss the incidence and role of anti-endothelial cell antibodies in transplant outcome
Discuss possible therapeutic strategies to prevent antibody-mediated activation of endothelial cells
Discuss emerging concepts of cellular autoimmunity in rejection of lung allografts
Discuss key hurdles to successful KPD
Discuss role of desensitization with KPD
Describe current participation in KPD by transplant centers in US.
Identify the challenges that the national kidney allocation system imposes on transplant programs.
Discuss Pathogenesis of ABMR Diagnostic criteria for ABMR Therapeutic options for ABMR Prognosis
Explain the role DSA plays on graft outcomes.
Describe basic pathology of antibody-mediated injury
Outline key diagnostic criteria for pathologic diagnosis of AMR
Describe the isolation and generation of expandable human nephron
Utilize discarded organs as a platform for kidney bioengineering and regeneration
Describe the role of scaffolding material in tissue engineering
Discuss how we are obtaining novel human tissues for immunological research through collaboration with the organ procurement organization
Discuss age-associated changes in T cell distribution and function throughout all life stages
Evaluate the role of the transcription factor KLF2 in controlling resident memory formation.
Discuss the nature of T cell exhaustion/dysfunction
Discuss challenges facing donor availability in heart transplantation
Review opportunities to expand the donor pool
Describe how Transmedics device can be used
Identify donor predictors of a heart that is suitable for transplantation
Discuss complications of intestinal transplantation
Identify and recognize biliary complications including leaks and obstructions.
Review salvage strategies
Describe how to avoid, identify and manage hepatic artery thrombosis
Discuss current therapy of CMV 2, new therapeutics for prevention and treatment, and the clinical settings these may be applied in
Discuss the practical applications of CMV CMI assay
Describe the progress in standardization of viral load assays and its implications for clinical management.
Discuss the clinical utility of viral load in assessing treatment response during therapy of cytomegalovirus infection.
Present contemporary approaches for immune monitoring in transplantation
Discuss the current immunosuppressive regimens used in vascularized composite allotransplantation
Assess the current state of the art in vascularized composite allografts
Define Vascularized Composite Allografts
Describe current and upcoming regulations governing VCA's
Explain the utility of peer mentoring programs in medical settings
Describe a program developed for use in pediatric transplantation
Describe health care transition and self-management: The process and its outcomes definition
Assess the health numeracy demand of communication tools
Discuss what major transplant programs have successfully established as educational programs for potential individuals interested in becoming a living donor
Summarize current best practices in reducing racial and income disparities in live donor kidney transplantation and living donation.
Identify methods to overcome barriers to such education.
Discuss practical approaches to assist transplant candidates to accept live donor kidney transplant.
Discuss the influence on the microbiota on alloimmune responses
Extrapolate how the microbiota may be targeted therapeutically to improve transplant outcomes
Discuss approaches to development of diagnostic tests and treatment paradigms.
Explain the role of microbiota in intestinal homeostasis
Review the current outcomes of clinical islet transplantation
Define strategies to improve these outcomes
Discuss donor selection criteria for successful islet isolation
Discuss quality control assessment of islets: its relevance and methodology
Discuss the costs of islet transplantation
Specify optimal post transplant testing to assess the risk of transmission events
Define the criteria for OPTN-defined increased risk donors
Define behaviors / conditions that constitute high infectious risk categorization of deceased donors
Discuss the risk of donor disease transmission in the context of recipient characteristics
identify limits of current DCD research
Name the challenges of organ procurement after circulatory arrest.
List the key factors including resources and donor and recipient risks which contribute to outcomes of DCD liver transplant.
Identify barriers to optimization of resource allocation, utilization, and outcome of DCD liver transplantation.
Identify at least three areas of adult facility infra-structure accomodations that will contribute to successful transition.
Name a least three key elements that facilitate positive transitions of care.
Discuss the relevance of three different metrics for evaluation of a successful transition program.
Recognize and anticipate specific barriers to transition of care for adolescents and young adults with transplants.
State the role of outcomes as a transition resource
Distinguish acceptable and unacceptable HLA mismatches
Define HLA epitope
List strategies to utilize HLA epitope matching to improve outcomes.
Assess whether HLA Epitope matching is ready for prime time use in clinical setting
Discuss disease stage and molecular diagnostics
Discuss epo generate Treg by the induction of TGFb by antigen presenting cells.
Compare predictive accuracy of the live donor KDPI with the deceased donor KDPI
Name causes of organ transplant loss
List mechanisms and limitations of immunosuppressive drugs
Discuss problems with implementing organ transplant tolerance, particularly antibody-mediated rejection
Define tolerance and establish its value relative to immunosuppression point out the benefits and risks
Discuss the real differences between "opt-out" and "opt in" system
Discuss the potential of social media in assisting identification of appropriate living donors
Explain the new approaches to the science of organ preservation.
Identify approaches that will lead to increasing live donor pool and what will impede do so
Name the steps leading to the removal of autoreactive B cells
Explain the function of autophagyin memory B cells.
Describe the mechanisms of selection and tolerance of autoreactive and nonautoreactive B cells from bone marrow to blood
Discuss the implication of dual antibody-expressing B cells for autoimmunity.
Discuss options to increase living donation
Discuss methods to advocate for living donation
Describe the current process for initial screening of living kidney donors
Describe how an electronic screening program can be implemented in a living donor program
Discuss NDD Trigering Chains
Explain Treg functions in the regulation of immune and transplant responses.
Define the roles of T cell metabolism and mTOR signaling in vivo
Discuss basic metabolic requirements of T cell responses
Discuss pharmacologic mechanisms to exploit T cell metabolism
Discuss the indications for Simultaneous liver kidney transplant
Discuss the overall implications of the use of SLK in the face of global organ shortages
Discuss the markers for irreversibility of renal dysfunction in patients with advanced hepatic failure
Discuss the prevalence of acute kidney injury and/or chronic kidney disease among adult liver transplant candidates
Discuss the immunologic advantage of simultaneous liver and kidney transplantation, particularly with respect to the humoral allo-immune response
Discuss the pathogenesis of Small-for-Size Syndrome
Discuss methods of portal inflow modulation.
Risks of right vs. left lobe donation
Evaluation of risk shifting from donor to recipient.
Discuss clinical applications of cell-free DNA sequencing
Discuss monitoring for post-transplant infections using cell-free DNA sequencing
Discuss current approaches for identification of biomarkers for diagnosis of acute and chronic rejection
Discuss the current status regarding identified biomarkers for diagnosis of acute and chronic rejection.
List the goals of screening for coronary artery disease
Review recent guidelines pertinent to the evaluation for and treatment of coronary disease in kidney transplant candidates
Explain how diastolic dysfunction can be treated to improve cardiac function and post-transplant outcomes.
Discuss potential impact of biomarkers on post transplant outcomes.
Describe cases of donor-derived disease transmission presenting as encephlitis investigated by CDC 2)
Recognize what makes an appropriate candidate with HIV for organ transplantation in 2015.
List methods of mitigating against the risk of disease transmissions
Identify risk factors associated with donors from areas of high incidence of endemic fungi, tuberculosis, and other geographically limited diseases
Review potential clinical clues to donor-derived infections due to drug resistant pathogens and donors
List the usual steps taken when an allocation or transplant event is expected to have wide media coverage.
Discuss the policies and bylaws that allow for urgent responses / policy changes, including the recent public policy proposals discussed by the OPTN Board of Directors in 2014-2015.
Discuss choice of topic, investigative methods and writing technique used to create major projects about transplantation
Discuss the decreasing volume of pancreas transplants performed in the United States.
Discuss importance of volume as it relates to outcome.
Identify present challenges to implementation of new beta cell replacement therapies
Review donor and recipient selection practices
Discuss infectious complications of cannabis use
Discuss drug interactions between cannabis and immunosuppression
Review rationale for current guidelines regarding marijuana use
Integrate clinical presentations of rejection and diagnosis
Relate histological lesions in the skin of VCA and potential outcomes
Discuss mechanisms of rejection in hand and face VCA
Discuss of symptoms and diagnosis in hand and face VCA
Discuss patient groups for uterus transplantation
Explain technique of uterus transplantation
Cite results of uterus transplantation in the human
Identify barriers of living and deceased organ donation and access to transplantation in minorities in US
Name national/ regional initiatives to improve organ donation and access to transplantation in minorities
Discuss what barriers are present for minority patients in terms of donation and access to transplantation
List methods for improvement in access to information for minority patients.
Identify risk factors for post-transplant hypertension
Identify 3 concepts for reducing CV morbidity in pediatric SOT recipients.
Discuss current management of CAC in children after transplant
Review post-transplant outcomes in obese pediatric recipients
Explain the impact of donor BMI on pediatric liver transplant recipient survival
Identify common barriers to medication approval
Describe strategies for providers to overcome barriers to patients' getting transplant medications approved
Compare and contrast medication affordability under Medicare, Medicaid and commercial insurance coverage
Identify optimal use of patient assistance programs including vouchers, copay cards, copay grants, premium grants, and complimentary drug
Describe key elements of discharge planning
Discuss the relationship between ischemia reperfusion injury (IRI) and primary graft dysfunction (PGD) after lung transplantation
Discuss the biological and cellular pathways implicated in the development of PGD after lung transplantation
Dissect mechanisms of the pathology propose therapeutic strategies
Discuss the consequences of ischemia reperfusion injury on transplant outcome
Discuss the feasibility of robot-assisted laparoscopic pancreas transplantation
Discuss advantages/disadvantages and prospectives for improvement in robot-assisted laparoscopic pancreas transplantation
Discuss the impact of obesity on dialysis and transplant outcomes
Discuss the surgical principles of minimal invasive, robotic assisted kidney transplantation.
Discuss current status of preclinical and clinical islet xenotransplantation
Discuss current understanding of the advantages of islet xenotransplantation
Describe the role of proper management of transplant recipient in Graft and recipient survival
Demonstrate the sgRNA and Cs9 nuclease based genome editing and its role in multiplex genetic engineering of pigs
Evaluate the impact of xenoantigen deletion on human antibody binding to pig cells
Review options for screening for BK
Discuss how to treat BK polyomavirus replication: reducing immunosuppression and role of adjunct therapies.
Illustrate how BKV nephropathy in a biopsy can be distinguised from rejection.
Describe current methods for BK virus diagnosis
Discuss the association between acute cellular rejection with key outcomes following liver transplantation.
Discuss key drug-drug interacstion between immunosuppressive agents and direct acting antiviral agents
Determine if there is any beenfit to altering immunosuppression regimens in patients with viral hepatitis
Review the evidence for use of mTOR inhibitors in patients with malignancy
Examine studies that have attempted conversion to calcineurin free immunosuppression
Explain the importance of pre-conception counselling in women with solid organ transplant
Discuss post-partum considerations in transplant recipients
Describe how the normal menstrual cycle and ovulation can be affected by chronic medical conditions and medications.
Discuss how changes in hormone status around the menopause transition can be managed by hormone therapy, and the safety of these therapies in a transplant patient.
Discuss unconventional Th17 alloimmune responses in allograft rejection.
Demonstrate a novel role of Notch1 in T cell proliferation, activation and regulation in alloimmunity.
Describe what is belatacept
Identify range of quality of kidney allografts as measured by KDPI being used for Simultaneous liver kidney transplants.
Describe how the Fibrosis was regulated during BOS development.
Discuss the connection between organ grafting and immunology and how they help each other.
Perceive the serious ethical dilemmas that have confronted clinicians doing transplants.
Explain the extreme importance of the texture of inflammation upon immunoregulation
Dsicuss how newly discovered immunoregulatory cells influence engraftment
Review the highlights of basic science abstracts at the ATC
Review the highlights of basic science findings in transplantation this year
Dsicuss the latest and most innovative topics in kidney, pancreas, liver and thoracic transplantation
Objective 4: Explain the challenges in the clinical care of solid organ and tissue transplantation as well as potential long-term complications.
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
Please answer the following:
Do you believe this activity was appropriate for the scope of your professional activities?
Was the educational content scientifically sound?
If faculty spoke about off-label or investigational uses of a product, was that information disclosed to you?
Was the mode of education effective to learning?
If you answered "No" to any of the above questions, please explain.
Did you perceive any product/service/company/commercial bias in any educational session you attended or materials you received?
If you answered "Yes" to the above question, please detail the situation below (e.g. session title, speaker name):
Were you solicited by sales personnel in an educational room (other areas do not matter) while you attended this educational activity?
If you answered "Yes" to the above question, please explain in detail (e.g. who, when, where):
How much did you learn as a result of this education program?
What specifically did you learn during this activity that you intend to integrate into your practice?

What questions have arisen in your practice for which you need answers/strategies that you can implement?

What patient/client problems or patient/client challenges do you feel you are not able to address appropriately or to your satisfaction?
What problems are your patients/clients communicating to you that need attention or follow up?

Are you interested in basic, intermediate or advanced level trainings?

What barriers might you have that would interfere with implementation of new information learned from this training?

How can this training (the overall meeting) be improved to better impact competence, performance and/or patient/client outcomes?

Additional comments:

Mr question